脑钠肽相关药物在心力衰竭治疗中的研究进展  

Progress of Brain Natriuretic Peptide Related Drugs in the Treatment of Heart Failure

作　　者：彭龙希[1] 李正翔[1] PENG Longxi;LI Zhengxiang(Tianjin Medical University General Hospital,Tianjin 300052)

机构地区：[1]天津医科大学总医院,天津300052

出　　处：《药学与临床研究》2019年第1期61-63,共3页Pharmaceutical and Clinical Research

摘　　要：心力衰竭是各种心脏疾病的终末期,已成为世界范围内主要公共卫生问题,为了更好地治疗心力衰竭,提高患者的生活质量,降低住院率和死亡率,新型药物在不断研发中。重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)、血管紧张素受体脑啡肽酶抑制剂(angiotensin receptor neprilysin inhibitor,ARNI)作为新型脑钠肽相关药物相继应用于临床,两者具有扩张静脉和动脉功能,从而降低前、后负荷,促进钠排泄和利尿、抑制RAAS和交感神经系统等多重作用。本文就脑钠肽相关药物在心力衰竭治疗中的研究进展作一综述。Heart failure is the end stage of various heart diseases and has become the major public health problem in the world.In order to better treat heart failure,improve the quality of life,reduce the rate of hospitalization and mortality,new drugs are being constantly explored.Recombinant human brain natriuretic peptide and angiotensin receptor enkephalin inhibitor,as new natriuretic peptide related drugs,have been applied to clinic successively.Both of them can dilate veins and arteries,thus reducing the pre and post load,promoting sodium excretion and diuresis,inhibiting RAAS and sympathetic nervous system.This article reviews the progress of natriuretic peptide related drugs in the treatment of heart failure.

关 键 词：心力衰竭 脑钠肽(BNP) 重组人脑利钠肽 血管紧张素受体脑啡肽抑制剂 

分 类 号：R972.4[医药卫生—药品] R541[医药卫生—药学]